GENSIGHT BIOLOGICS SA (SIGHT.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:SIGHT - FR0013183985 - Common Stock
SIGHT.PA Key Statistics, Chart & Performance
The current stock price of SIGHT.PA is 0.082 EUR. In the past month the price decreased by -20.85%. In the past year, price decreased by -71.18%.
SIGHT.PA Technical Analysis
SIGHT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA. SIGHT.PA may be in some trouble as it scores bad on both profitability and health.
SIGHT.PA Financial Highlights
Over the last trailing twelve months SIGHT.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 78.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -205.69% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SIGHT.PA Forecast & Estimates
11 analysts have analysed SIGHT.PA and the average price target is 0.44 EUR. This implies a price increase of 434.88% is expected in the next year compared to the current price of 0.082.
For the next year, analysts expect an EPS growth of 35.4% and a revenue growth 29.37% for SIGHT.PA
SIGHT.PA Ownership
About SIGHT.PA
Company Profile
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company is headquartered in Paris, Ile-De-France and currently employs 13 full-time employees. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Company Info
GENSIGHT BIOLOGICS SA
74 Rue du Faubourg Saint-Antoine
Paris ILE-DE-FRANCE FR
Employees: 16
Phone: 33176217220
GENSIGHT BIOLOGICS SA / SIGHT.PA FAQ
What does SIGHT do?
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. The company is headquartered in Paris, Ile-De-France and currently employs 13 full-time employees. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
What is the stock price of GENSIGHT BIOLOGICS SA today?
The current stock price of SIGHT.PA is 0.082 EUR. The price increased by 2.12% in the last trading session.
Does GENSIGHT BIOLOGICS SA pay dividends?
SIGHT.PA does not pay a dividend.
How is the ChartMill rating for GENSIGHT BIOLOGICS SA?
SIGHT.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is GENSIGHT BIOLOGICS SA (SIGHT.PA) stock traded?
SIGHT.PA stock is listed on the Euronext Paris exchange.
How is the valuation of GENSIGHT BIOLOGICS SA (SIGHT.PA) based on its PE ratio?
GENSIGHT BIOLOGICS SA (SIGHT.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
What is GENSIGHT BIOLOGICS SA worth?
GENSIGHT BIOLOGICS SA (SIGHT.PA) has a market capitalization of 15.62M EUR. This makes SIGHT.PA a Nano Cap stock.